Laurus Labs Limited (LAURUSLABS.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹2,139.80 (+3.87%) as of
Key statistics
- Market cap
- 1.16T
- P/E (TTM)
- 105.77
- Forward P/E
- 71.34
- EPS (TTM)
- 20.23
- Dividend yield
- 0.12%
- 52-week range
- 913.35 – 2,143.45
- Beta
- 0.34
- Revenue (TTM)
- 72.7B
- Profit margin
- 15.04%
- Analyst target
- ₹1,703.07
- Volume
- 111.02k
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 7,059
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.